4-phenyl-4-oxo-butanoic acid derivatives inhibitors of kynurenine 3- hydroxylase

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 20, 1998, Pages 2907-2912

  Giordani, Antonio ^a   Pevarello, Paolo ^a   Cini, Massimo ^a   Bormetti, Rita ^a   Greco, Felicita ^a   Toma, Salvatore ^a   Speciale, Carmela ^a   Varasi, Mario ^a  

^a PFIZER INC   (United States)

Author keywords

Enzyme inhibition; Hydroxylase; Kynurenine; Neuroprotection; Stereoselectivity

Indexed keywords

2 BENZYL 4 (3,4 DICHLOROPHENYL) 4 OXO BUTANOIC ACID; 2 HYDROXY 4 (3,4 DICHLOROPHENYL) 4 OXO BUTANOIC ACID; 4 PHENYL 4 OXO BUTANOIC ACID DERIVATIVE; BUTYRIC ACID DERIVATIVE; ENZYME INHIBITOR; EXCITATORY AMINO ACID RECEPTOR; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; KYNURENINE 3 MONOOXYGENASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOLINIC ACID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DIASTEREOISOMER; DRUG SELECTIVITY; DRUG SPECIFICITY; ENANTIOMER; ENZYME INHIBITION; LIVER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; STEREOCHEMISTRY; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TRYPTOPHAN METABOLISM;

ANIMALS; BRAIN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KYNURENINE 3-MONOOXYGENASE; LIVER; MIXED FUNCTION OXYGENASES; PHENYLBUTYRATES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN;

EID: 0032552919     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00517-4     Document Type: Article

References (20)

1. 1 Schwarcz, R.; Foster, A.C.; French, E. D.; Whetsell, W. O., Jr.; Koehler, C. Life Sci. 1984, 35, 19-32
2. 2. Choi, D. W.; Rothman, S. M. Annu. Rev. Neurosci. 1990, 13, 171-182.
3. 3. Meldrum, B. S.; Garthwaite, J. Trends Pharmacol. Sci. 1990, 11, 379-387.
4. 4. Bigge, C. F.; Malone, T. C. Curr. Opin. Therap. Pat. 1993, 7, 951-983.
5. 5. Muir, K. W.; Lees, K. R. Stroke 1995, 503, 26-34.
6. 6. Stone, T. W. Pharmacol. Rev. 1993, 45, 309-379.
7. 7. Pellicciari, R.; Natalini, B.; Costantino, G.; Mahmoud, M. R.; Mattoli, .; Sadeghpour, B. M.; Moron, F.; Chiarugi, A.; Carpenedo, R. J. Med. Chem 1994, 37, 647-656.
8. 8. Giordani, A.; Corti, L.; Cini, M.; Bormetti, M.; Marconi, M.; Veneroni, C.; Speciale, C.; Varasi, M. Adv. Exp. Med. Biol. (Recent Advances in Tryptophan Research) 1996, 398, 449-453.
9. 9. Varasi, M.; Pevarello, P.; Giordani, A.; Schwarcz, R.; Speciale, C. First Italian-Swiss Meeting on Medicinal Chemistry, Torino, 1997.
10. 10. Giordani, A.; Corti, L.; Cini, M.; Bormetti, R.; Marconi, M.; Veneroni, O.; Speciale, C.; Varasi, M. Adv. Exp. Med. Biol. (Recent Advances in Tryptophan Research) 1996, 398, 531-534.
11. 11. Röver, S.; Cesura, A. M.; Huguenin, P.; Kettler, R.; Szente, A. J. Med. Chem. 1997, 40, 4378-4385.
12. 3H)-KYN (10 Ci/mmol) and 3 μl of different concentration of inhibitor solutions. After the incubation, the reaction was terminated by addition of 300 μl of 7.5% (w/v) activated charcoal, and centrifuged for 7 min. A 75μl aliquot of supernatant was transferred to optiplate and liquid scintillation added. The optiplates were vortexed and the radioactivity counted in a microplate scintillation counter. The apparent discrepancies in potency as compared to the rat brain enzyme seem to be due to the lesser sensitivity of the radiometric detection rather than to different tissue specificity.
13. 13. KYN-3-OHase activity was measured in a crude mitochondrial preparation of whole rat forebrain (Carpenedo, R. A. Chianigi, P.; Russi, G.; Lombardi, V.; Carlá, R.; Pellicciari, R.; Mattoli, L.; Moroni, F. Neuroscience 1994, 61, 237-243) and in human liver recombinant enzyme expressed in trasformed E. Coli (Magagnin, S.; Covini, N.; Bormetti, R.; Cini, M.; Speciale, C.; Benatti, L. Society for Neuroscience, New Orleans, LA, Oct 25-30,1997;P903.6) according to the method described by Carpenedo, R. A. et al.
14. 13. KYN-3-OHase activity was measured in a crude mitochondrial preparation of whole rat forebrain (Carpenedo, R. A. Chianigi, P.; Russi, G.; Lombardi, V.; Carlá, R.; Pellicciari, R.; Mattoli, L.; Moroni, F. Neuroscience 1994, 61, 237-243) and in human liver recombinant enzyme expressed in trasformed E. Coli (Magagnin, S.; Covini, N.; Bormetti, R.; Cini, M.; Speciale, C.; Benatti, L. Society for Neuroscience, New Orleans, LA, Oct 25-30,1997;P903.6) according to the method described by Carpenedo, R. A. et al.
15. 14.] Takikawa, O.; Yoshida, R.; Kido, R.; Hayaishi, J. J. Biol. Chem. 1986,261, 3648-3653.
16. 15. Okuno, E.; Schmidt. W.; Parks, D. A.; Nakamura, M.; Schwarcz, R. J. Neurochem. 1991, 57, 533-538.
17. 4. After centifugation, supernatants were directly used for the measurement of 3,4 dihydroxybenzoic acid. The concentration of 3,4 dihydroxybenzoic acid was measured by HPLC with coulometric detection (det. 1 +0.05V, det 2 +0.2V) using a 10 cm C18 reversed phase (3μm) column with a mobile phase containing water / acetonitrile / trifluoroacetic acid (95 / 5 / 0.05). The flow rate was 1 ml/min.
18. 17. Dixit, A.; Roche, T. E. Arch. Biochem. Biophys. 1984, 233, 50-63.
19. 18. KYN-3-OHase activity was measured in human liver recombinant enzyme expressed in COS-1 cells according to Breton J. et al., manuscript in preparation, and following the method described in 12].
20. -